Matteo Duca
Impact in
-
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Lung Cancer Research Studies
- CAR-T cell therapy research
-
- Lung Cancer Treatments and Mutations
Papers in
- Oncology 13
- Cancer Treatment and Pharmacology 5
- HER2/EGFR in Cancer Research 5
- Cancer Immunotherapy and Biomarkers 3
- Colorectal Cancer Treatments and Studies 2
- Co-authors
- Silvia Damian (11 shared papers)Sara Cresta (8 shared papers)Filippo de Braud (10 shared papers)Biagio Paolini (3 shared papers)Jean‐Pascal Machiels (3 shared papers)Lorenzo Pilla (1 shared paper)Francesca Toffalorio (1 shared paper)Anna Tessari (3 shared papers)
- Journals
- Annals of Oncology (2 papers)Journal of Clinical Oncology (2 papers)Scientific Reports (1 paper)ESMO Open (1 paper)The Breast (1 paper)
- Partner nations
- ItalyUnited StatesBelgium
In The Last Decade
Matteo Duca
17 papers receiving 141 citations
Peers
Comparison fields: 5 of 35
- Oncology 81
- Pulmonary and Respiratory Medicine 57
- Immunology 36
- Cancer Research 15
- Reproductive Medicine 8
Countries citing papers authored by Matteo Duca
This map shows the geographic impact of Matteo Duca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matteo Duca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matteo Duca more than expected).
Fields of papers citing papers by Matteo Duca
This network shows the impact of papers produced by Matteo Duca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matteo Duca. The network helps show where Matteo Duca may publish in the future.
Co-authors
The 25 scholars most cited alongside Matteo Duca, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors | 2022 | 40 |
| 2 | 2013 | 34 | |
| 3 | 2018 | 27 | |
| 4 | 2024 | 6 | |
| 5 | 2021 | 5 | |
| 6 | 2014 | 4 | |
| 7 | 2021 | 4 | |
| 8 | 2020 | 4 | |
| 9 | 2022 | 3 | |
| 10 | 2019 | 3 | |
| 11 | 2016 | 3 | |
| 12 | 2013 | 3 | |
| 13 | 2018 | 2 | |
| 14 | 2014 | 1 | |
| 15 | 2025 | 1 | |
| 16 | 2014 | 1 | |
| 17 | 2016 | 1 | |
| 18 | 2024 | 1 |
About Matteo Duca
Matteo Duca is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Immunology, having authored 18 papers that have together received 143 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (5 papers), HER2/EGFR in Cancer Research (5 papers), Cancer Immunotherapy and Biomarkers (3 papers), Cancer Genomics and Diagnostics (3 papers), Immunotherapy and Immune Responses (3 papers), Advanced Breast Cancer Therapies (3 papers), Colorectal Cancer Treatments and Studies (2 papers) and Breast Cancer Treatment Studies (2 papers). The work is most often cited by research in Oncology (81 citations), Pulmonary and Respiratory Medicine (57 citations), Immunology (36 citations), Cancer Research (15 citations) and Reproductive Medicine (8 citations). Matteo Duca has collaborated with scholars based in Italy, United States and Belgium. Frequent co-authors include Silvia Damian, Sara Cresta, Filippo de Braud, Biagio Paolini, Jean‐Pascal Machiels, Lorenzo Pilla, Francesca Toffalorio, Anna Tessari, Fabio Conforti and Gianluca Spitaleri. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Scientific Reports, ESMO Open and The Breast.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.